Tongxin Medical Equipment Valuation, Funding & Investors

Gameto is a New York-headquartered biotechnology company engineering stem cell-derived therapies for reproductive health disorders. Their platform reprograms human induced pluripotent stem cells into functional ovarian and endometrial cell lines using specific transcription factors that enable hormone production and response. Fertilo advances infertility treatments by enhancing IVF and egg freezing outcomes through improved egg maturation. Deovo develops organoids replicating the female reproductive tract for drug screening. Ameno addresses primary ovarian insufficiency and menopause via cell-based interventions. The company maintains partnerships with academic institutions like Columbia University and has initiated clinical studies for Fertilo in collaboration with reproductive clinics across Europe and the United States.

Conexeu Sciences Inc is an early-stage medical technology company. The company develops and supplies collagen-based technologies that helps doctors and patients regenerate tissue naturally, safely, and effectively. The company is focused on developing regenerative biomaterials that address relative needs in wound care, dentistry, and aesthetics. The company seek to provide physicians with device-based solutions that improve healing, restore soft tissue, and enhance patient outcomes across multiple clinical settings.

Graphy Inc is engaged in developing customized materials (3D printing materials) based on oligomer synthesis technology, photo-curable resins and materials for 3D printing in the dental industry. Its products include Shape Memory Aligner, Permanent C&B, Denture Base, Mouth Guard, and others.

Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Viromed Medical AG is a medical technology company. It focuses on using cold plasma technology to develop medical solutions that protect people from viruses, bacteria, and multi-resistant germs. Viromed's product offerings include ViroCAP, a medical device based on cold plasma technology for treating wounds; ViroCAP derma-podo, a medical device that uses cold atmospheric plasma therapy for skin and foot care; and a Raumluftentkeimer. The company covers the entire value chain from research and development to production, logistics, marketing, and sales of its products.